Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): A targeted oncoprotein strikes back

Keyphrases

• Abl Kinase 50%
• Anticancer Treatment 25%
• BCR-ABL 100%
• BCR-ABL Fusion Gene 25%
• Bell 25%
• Cancer Research 25%
• Chronic Myeloid Leukemia 50%
• Fusion Protein 25%
• Glivec 100%
• Growth Advantage 25%
• Identified Genes 25%
• Imatinib 100%
• Imatinib Mesylate 25%
• Imatinib Resistance 25%
• Imatinib Therapy 25%
• Kinase Activity 25%
• Kinase Domain 25%
• Kinase Inhibitor 100%
• Leukemia 75%
• Leukemia Cells 25%
• Malignant Transformation 25%
• Molecular Abnormalities 25%
• Oncoprotein 100%
• Overcoming Resistance 25%
• Philadelphia 50%
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia 100%
• Point mutation 50%
• Resistant Disease 25%
• Secondary mutation 25%
• Signaling Genes 25%
• STI571 100%
• Targeted Cancer Therapy 25%
• Therapeutic Approaches 25%

Biochemistry, Genetics and Molecular Biology

• Adenosine Triphosphate 9%
• Anticancer 18%
• Chimeric Protein 9%
• Gene Mutation 9%
• Imatinib 100%
• Kinase 100%
• Malignant Transformation 9%
• Myeloid 18%
• Philadelphia Chromosome 100%
• Phosphotransferase 100%
• Point Mutation 18%